Calonder, Claudio, Lotz, Gregor, Benstein, Karin, Bloem, Karien, Buddinger, Harm, Elm, Stefanie, Fernandez, Elena, Gorovits, Boris, Grudzinska-Goebel, Joanna, Janssen, Melody, Jawa, Vibha, Luo, LinLin, Malisauskas, Mantas, Michaut, Lydia, Schäfer, Martin, Spindeldreher, Sebastian, Ullmann, Martin, Weldingh, Karin Nana, Kromminga, Arno, Snoeck, Veerle, Kramer, Daniel and Joanne, Goodman (2022) When to Extend Monitoring of Anti-drug Antibodies for High-risk Biotherapeutics in Clinical Trials: an Opinion from the European Immunogenicity Platform. The AAPS journal, 24 (3). p. 68. ISSN 1550-7416

Abstract

The determination of a tailored anti-drug antibody (ADA) testing strategy is based on the immunogenicity risk assessment to allow a correlation of ADAs with changes to pharmacokinetics, efficacy, and safety. The clinical impact of ADA formation refines the immunogenicity risk assessment and defines appropriate risk mitigation strategies. Health agencies request for high-risk biotherapeutics to extend ADA monitoring for patients that developed an ADA response to the drug until ADAs return to baseline levels. However, there is no common understanding in which cases an extension of ADA follow-up sampling beyond the end of study (EOS) defined in the clinical study protocol is required. Here, the Immunogenicity Strategy Working Group of the European Immunogenicity Platform (EIP) provides recommendations on requirements for an extension of ADA follow-up sampling in clinical studies where there is a high risk of serious consequences from ADAs. The importance of ADA evaluation during a treatment-free period is recognized but the decision whether to extend ADA monitoring at a predefined EOS should be based on evaluation of ADA data in the context of corresponding clinical signals. If the clinical data set shows that safety consequences are minor, mitigated, or resolved, further ADA monitoring may not be required despite potentially detectable ADAs above baseline. Extended ADA monitoring should be centered on individual patient benefit.

Item Type:	Article
Keywords:	Antibodies Humans
Date Deposited:	03 Jan 2023 00:45
Last Modified:	03 Jan 2023 00:45
URI:	https://oak.novartis.com/id/eprint/46804